ArticleInternational journal of nanomedicine2025
Os Draconis-Derived Nanoparticles Improve Insomnia Symptoms by Activating Calcium-Dependent 5-HT Release and the Vagal-NTS Pathway.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Os draconis (OD), a traditional Chinese medicine from fossil mammalian bones, effectively treats insomnia and anxiety. Its usage conflicts with the laws, causing a shortage. This research clarifies OD's pharmacodynamic mechanisms, aiming to establish a scientific basis for developing novel artificial substitutes. Methods: This research used a mouse chronic insomnia paradigm to assess an os draconis decoction (DOD). DOD was digested in vitro, and the resultant nanoparticles (OD-NPs) were analyzed by scanning electron microscopy, dynamic light scattering, X-ray diffraction, and Fourier transform infrared spectroscopy. The in vivo effects were evaluated using behavioral tests, Nissl staining, neuronal activity in the nucleus tractus solitarii (NTS), and plasma 5-HT levels. In vitro mechanistic investigations used FITC-labeled OD-NPs to detect cellular uptake. The research used calcium channel blockers to examine changes in intracellular Ca Results: After DOD treatment, significantly improved movement in the Open field, brain malondialdehyde (MDA) and plasma tumor necrosis factor-α (TNF-α) were reduced, increased hippocampal Nissl bodies, and alleviated neuronal damage. Digested DOD formed numerous sub-1000 nm spindle particles. Its composition remained carbonate hydroxyapatite (F-rich), but crystallinity decreased. DOD elevated plasma 5-HT and c-fos expression in the NTS. In vitro, OD-NPs were uptaken by cells, increasing supernatant 5-HT and cytosolic calcium. This upregulated TPH1 and DdC expression, a trend unaffected by Ca Conclusion: This is the first research to suggest that oral DOD is digested into OD-NPs, which are then internalized by enterochromaffin cells. This absorption initiates calcium signaling, boosts 5-HT release, and then activates the vagus nerve-NTS pathway, thereby regulating central nervous system activity. This research provides scientific proof for the clinical application of OD, lays the groundwork for the development of artificial alternatives, and generates ideas for future traditional Chinese medicine research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.